Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Liabilities and Shareholders Equity (2017 - 2022)

Historic Liabilities and Shareholders Equity for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $71.6 million.

  • Iterum Therapeutics' Liabilities and Shareholders Equity fell 2729.78% to $71.6 million in Q3 2022 from the same period last year, while for Dec 2022 it was $232.3 million, marking a year-over-year decrease of 4349.75%. This contributed to the annual value of $91.5 million for FY2021, which is 17905.89% up from last year.
  • As of Q3 2022, Iterum Therapeutics' Liabilities and Shareholders Equity stood at $71.6 million, which was down 2729.78% from $76.7 million recorded in Q2 2022.
  • Iterum Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $145.5 million during Q2 2018, with a 5-year trough of $25.8 million in Q4 2019.
  • Its 5-year average for Liabilities and Shareholders Equity is $76.3 million, with a median of $80.4 million in 2022.
  • Per our database at Business Quant, Iterum Therapeutics' Liabilities and Shareholders Equity plummeted by 7368.88% in 2019 and then skyrocketed by 27465.55% in 2021.
  • Over the past 5 years, Iterum Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $97.9 million in 2018, then crashed by 73.69% to $25.8 million in 2019, then increased by 27.34% to $32.8 million in 2020, then soared by 179.06% to $91.5 million in 2021, then dropped by 21.81% to $71.6 million in 2022.
  • Its Liabilities and Shareholders Equity was $71.6 million in Q3 2022, compared to $76.7 million in Q2 2022 and $84.1 million in Q1 2022.